China's regulatory agency, the National Medical Products Administration, on 5 February granted conditional approval to Sinovac Biotech Ltd.'s inactivated virus-based coronavirus vaccine CoronaVac, the move coming just ahead of the busiest annual travel period in the country as it kicks off the Lunar New Year holiday period.
China Approves SinoVac's CoronaVac, As 50.6% Efficacy Reported
Slow Roll-Out Despite Looming New Year Holiday
SinoVac has obtained conditional approval in China for its COVID-19 vaccine CoronaVac, while new clinical data released by the company show a large difference in protection rates in two separate trials, in one case barely above the WHO threshold.
